The convergence of bortezomib, a proteasome-targeting agent, with an HDAC6 inhibitor, specifically directed at aggregates within tumor cells, engenders heightened accumulation of polyubiquitinated proteins, consequently inducing increased cellular stress and death [81, 82]. The gene discussed is HDAC6; the disease is neoplasm.